Published in Proc Natl Acad Sci U S A on December 01, 1976
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet (2006) 7.53
Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev (2005) 3.38
Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A (1998) 3.24
ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab (2006) 2.55
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A (2009) 2.23
Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol (2006) 1.75
Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest (1997) 1.61
Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A (2005) 1.55
Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology (2007) 1.51
Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest (1992) 1.45
Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet (1997) 1.37
Studies of the DMP1 57-kDa functional domain both in vivo and in vitro. Cells Tissues Organs (2008) 1.26
Renal Na(+)-phosphate cotransport in murine X-linked hypophosphatemic rickets. Molecular characterization. J Clin Invest (1994) 1.22
The Gy mutation: another cause of X-linked hypophosphatemia in mouse. Proc Natl Acad Sci U S A (1986) 1.14
New intragenic deletions in the Phex gene clarify X-linked hypophosphatemia-related abnormalities in mice. Mamm Genome (2004) 1.10
Evidence for an intrinsic renal tubular defect in mice with genetic hypophosphatemic rickets. J Clin Invest (1979) 1.08
Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone (2012) 1.07
Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine. J Biol Chem (2008) 1.04
Correction of proximal tubule phosphate transport defect in Hyp mice in vivo and in vitro with indomethacin. Proc Natl Acad Sci U S A (2003) 1.03
Effect of spermine synthase deficiency on polyamine biosynthesis and content in mice and embryonic fibroblasts, and the sensitivity of fibroblasts to 1,3-bis-(2-chloroethyl)-N-nitrosourea. Biochem J (2000) 1.00
Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J Biol Chem (2009) 0.98
The rachitic tooth. Endocr Rev (2013) 0.96
Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology (2009) 0.95
Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. Bone (2009) 0.95
Hereditary hypophosphatemic rickets with hypercalciuria: a study for the phosphate transporter gene type IIc and osteoblastic function. J Bone Miner Metab (2007) 0.94
Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J Bone Miner Res (2013) 0.93
X-linked hypophosphatemia: the mutant gene is expressed in teeth as well as in kidney. Am J Hum Genet (1990) 0.93
The molecular background to hypophosphataemic rickets. Arch Dis Child (2000) 0.91
Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphatemic rickets. J Clin Invest (1990) 0.91
Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology (2012) 0.90
The PHEX transgene corrects mineralization defects in 9-month-old hypophosphatemic mice. Calcif Tissue Int (2008) 0.90
Phosphate: known and potential roles during development and regeneration of teeth and supporting structures. Birth Defects Res C Embryo Today (2008) 0.90
Expression and distribution of SIBLING proteins in the predentin/dentin and mandible of hyp mice. Oral Dis (2010) 0.90
Abnormal parathyroid hormone stimulation of 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the hypophosphatemic mouse. Evidence for a generalized defect of vitamin D metabolism. J Clin Invest (1986) 0.89
New mouse models for metabolic bone diseases generated by genome-wide ENU mutagenesis. Mamm Genome (2012) 0.88
Hypophosphatemia and growth. Pediatr Nephrol (2012) 0.88
Gene mapping of mineral metabolic disorders. J Inherit Metab Dis (1989) 0.88
Defective binding of macrophages to bone in rodent osteomalacia and vitamin D deficiency. In vitro evidence for a cellular defect and altered saccharides in the bone matrix. J Clin Invest (1983) 0.87
Alkaline phosphatase activity does not mediate phosphate transport in the renal-cortical brush-border membrane. Biochem J (1980) 0.87
Primary cultures of renal epithelial cells from X-linked hypophosphatemic (Hyp) mice express defects in phosphate transport and vitamin D metabolism. Am J Hum Genet (1988) 0.87
Increased renal catabolism of 1,25-dihydroxyvitamin D3 in murine X-linked hypophosphatemic rickets. J Clin Invest (1988) 0.87
Protective roles of DMP1 in high phosphate homeostasis. PLoS One (2012) 0.86
Dosage effect of a Phex mutation in a murine model of X-linked hypophosphatemia. Calcif Tissue Int (2013) 0.85
Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis. J Biol Chem (2010) 0.85
Comparative map for mice and humans. Mamm Genome (1991) 0.81
Autosomal hypophosphataemic bone disease responds to 1,25-(OH)2D3. Arch Dis Child (1981) 0.79
Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice. Endocrinology (2012) 0.79
Healing of rickets with phosphate supplementation in the hypophosphatemic male mouse. J Clin Invest (1981) 0.78
The William Allan Memorial Award address: On phosphate transport and genetic screening. "Understanding backward--living forward" in human genetics. Am J Hum Genet (1979) 0.75
RAS in FGF23: another piece in the puzzle. J Clin Endocrinol Metab (2014) 0.75
X-linked hypophosphatemia (familial or sex-linked vitamin-D-resistant rickets). X-linked hypophosphatemic (Hyp) mice. Am J Pathol (1985) 0.75
What use is the human genome for understanding the mouse? Genome Biol (2001) 0.75
Cytogenetic approaches to mouse models of human genetic diseases. Am J Pathol (1980) 0.75
Molecular characterisation of the Hyp deletion and an improved assay for its detection. Bone (2011) 0.75
Mutation watch: PEX PLUS? Gene(s) for X-linked hypophosphatemia and deafness. Mamm Genome (1997) 0.75
Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6. J Hered (1976) 1.72
Loss of a parathyroid hormone-sensitive component of phosphate transport in X-linked hypophosphatemia. Science (1972) 1.48
Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med (1972) 1.46
Animal models--a neglected medical resource. N Engl J Med (1969) 1.43
The distribution of p-aminohippuric acid in rat kidney slices. I. Tubular localization. Kidney Int (1973) 1.33
Serum parathyroid hormone in X-linked hypophosphatemia. Science (1971) 1.22
Familial hypophosphatemic rickets: defective transport of inorganic phosphate by intestinal mucosa. Science (1973) 1.20
DETERMINATION ON A MICRO SCALE OF CONCENTRATION AND SPECIFIC RADIOACTIVITY OF INORGANIC PHOSPHATE IONS IN WHOLE BLOOD AND PACKED RED CELLS. Scand J Clin Lab Invest (1964) 1.12
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res (1991) 3.89
Advocacy and compliance in genetic screening. Behavior of physicians and clients in a voluntary program of testing for the Tay-Sachs gene. N Engl J Med (1974) 3.47
Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology (2001) 2.87
Distribution of ribosomal gene length variants among mouse chromosomes. Proc Natl Acad Sci U S A (1982) 2.66
The use of biochemical data in screening for mutant alleles and in genetic counselling. Ann Hum Genet (1974) 2.43
Knowledge about and attitudes toward genetic screening among high-school students: the Tay-Sachs experience. Pediatrics (1977) 2.29
Beta-thalassemia disease prevention: genetic medicine applied. Am J Hum Genet (1984) 2.27
Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med (1992) 2.27
The frequency of genetic disease and congenital malformation among patients in a pediatric hospital. Can Med Assoc J (1973) 2.22
The effect of Mendelian disease on human health: a measurement. Am J Med Genet (1985) 2.18
Transient tyrosinemia of the newborn: dietary and clinical aspects. Pediatrics (1967) 2.15
Purkinje cell degeneration, a new neurological mutation in the mouse. Proc Natl Acad Sci U S A (1976) 2.14
Screening, counselling and treatment of hereditary metabolic disease; a survey of resources in Canada. Can Med Assoc J (1974) 2.11
The beta3A subunit gene (Ap3b1) of the AP-3 adaptor complex is altered in the mouse hypopigmentation mutant pearl, a model for Hermansky-Pudlak syndrome and night blindness. Hum Mol Genet (1999) 2.09
Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology (2000) 2.08
A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med (1984) 2.06
A private view of heterozygosity: eight-year follow-up study on carriers of the Tay-Sachs gene detected by high school screening in Montreal. Am J Med Genet (1984) 2.04
Cost-benefit analysis of a thalassemia disease prevention program. Am J Public Health (1985) 1.99
The HUGO Mutation Database Initiative. Science (1998) 1.95
Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet (1996) 1.94
Carrier screening for Tay-Sachs disease. Lancet (1990) 1.92
On the application of knowledge to the patient with genetic disease. Prog Med Genet (1973) 1.84
Mus poschiavinus Y chromosome in the C57BL/6J murine genome causes sex reversal. Science (1982) 1.81
Evidence that Sry is expressed in pre-Sertoli cells and Sertoli and granulosa cells have a common precursor. Dev Biol (2001) 1.81
Osteoblasts isolated from mouse calvaria initiate matrix mineralization in culture. J Cell Biol (1983) 1.80
Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med (1995) 1.78
Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone (2002) 1.77
Science's neglected legacy. Nature (2000) 1.77
Fat (fat) and tubby (tub): two autosomal recessive mutations causing obesity syndromes in the mouse. J Hered (1991) 1.76
Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6. J Hered (1976) 1.72
Proof of "disease causing" mutation. Hum Mutat (1998) 1.68
Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. Am J Hum Genet (1996) 1.68
What young people think and do when the option for cystic fibrosis carrier testing is available. J Med Genet (1993) 1.68
Genetic control of primary sex determination in mice. Annu Rev Genet (1986) 1.68
Ovarian teratomas in mice are derived from oocytes that have completed the first meiotic division. Nature (1977) 1.68
Assignment of genes to regions of mouse chromosomes. Proc Natl Acad Sci U S A (1978) 1.67
Perinatal metabolism of vitamin D. Am J Clin Nutr (2000) 1.67
Sry induces cell proliferation in the mouse gonad. Development (2000) 1.65
Genetics and Medicine: an evolving relationship. Science (1978) 1.65
Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab (2000) 1.65
A Y-encoded subunit of the translation initiation factor Eif2 is essential for mouse spermatogenesis. Nat Genet (2001) 1.65
Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum Mol Genet (1997) 1.64
Demonstration in mouse of X-ray induced deletions for a know enzyme structural locus. Nature (1974) 1.63
Hereditary leucodystrophy in the mouse: the new mutant twitcher. Brain (1980) 1.61
Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics (2001) 1.60
The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res (1997) 1.53
Geographic origin of the Y chromosomes in "old" inbred strains of mice. Mamm Genome (1992) 1.53
Replacement therapy for inherited enzyme deficiency: liver orthotopic transplantation in Niemann-Pick disease type A. Am J Med Genet (1977) 1.51
Recommendations for locus-specific databases and their curation. Hum Mutat (2008) 1.49
Direct molecular identification of the mouse pink-eyed unstable mutation by genome scanning. Science (1991) 1.49
Loss of a parathyroid hormone-sensitive component of phosphate transport in X-linked hypophosphatemia. Science (1972) 1.48
Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone (2000) 1.46
Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med (1972) 1.46
Renal handling of phosphate in vivo and in vitro by the X-linked hypophosphatemic male mouse: evidence for a defect in the brush border membrane. Kidney Int (1978) 1.45
The defect in transcellular transport of phosphate in the nephron is located in brush-border membranes in X-linked hypophosphatemia (Hyp mouse model). Can J Biochem (1978) 1.45
Neonatal hypertyrosinemia and evidence for deficiency of ascorbic acid in Arctic and subarctic peoples. Can Med Assoc J (1975) 1.42
cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics (1996) 1.41
Migration of mesonephric cells into the mammalian gonad depends on Sry. Mech Dev (1999) 1.41
Novel PKU mutation on haplotype 2 in French-Canadians. Am J Hum Genet (1989) 1.40
Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med (1978) 1.40
Abnormal spermiogenesis in quaking, a myelin-deficient mutant mouse. Biol Reprod (1971) 1.38
Ank3 (epithelial ankyrin), a widely distributed new member of the ankyrin gene family and the major ankyrin in kidney, is expressed in alternatively spliced forms, including forms that lack the repeat domain. J Cell Biol (1995) 1.37
Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med (1980) 1.37
[Tay-Sachs disease: prenatal detection and diagnosis]. Union Med Can (1972) 1.36
Labile methyl group balances in the human: the role of sarcosine. Metabolism (1980) 1.34
X linkage of phosphoglycerate kinase in the mouse. Biochem Genet (1974) 1.34
Endogenous renal clearance rates of free amino acids in pre-pubertal children. (Employing an accelerated procedure for elution chromatography of basic amino acids on ion exchange resin). Pediatrics (1965) 1.34
Genetic organization of the agouti region of the mouse. Genetics (1987) 1.33
Phenylketonuria: epitome of human biochemical genetics (first of two parts). N Engl J Med (1980) 1.30
Genetic and molecular analysis of recessive alleles at the pink-eyed dilution (p) locus of the mouse. Proc Natl Acad Sci U S A (1992) 1.30
Collagen changes in the human uterine cervix at parturition. Am J Obstet Gynecol (1978) 1.30
Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcif Tissue Int (1983) 1.30
Use of dithiothreitol to correct cystine storage in cultured cystinotic fibroblasts. Lancet (1970) 1.30
Genetic variants of Tay-Sachs disease: Tay-Sachs disease and Sandhoff's disease in French Canadians, juvenile Tay-Sachs disease in Lebanese Canadians, and a Tay-Sachs screening program in the French-Canadian population. Prog Clin Biol Res (1977) 1.30
Vitamin D supplementation during pregnancy: effect on neonatal calcium homeostasis. J Pediatr (1986) 1.29
Autosomal phosphoglycerate kinase linked to mouse major histocompatibility complex. Mol Gen Genet (1978) 1.29
Thiamine-responsive maple-syrup-urine disease. Lancet (1971) 1.29
The chromosomal location of ribosomal DNA in the mouse. Chromosoma (1974) 1.29
Polymorphism of kidney pyruvate kinase in the mouse is determined by a gene, Pk-3, on chromosome 9. Biochem Genet (1981) 1.29
Familial cold urticaria. Clin Exp Dermatol (1993) 1.29
Hyperparathyroidism as the cause of hyperaminoaciduria and phosphaturia in human vitamin D deficiency. Pediatr Res (1967) 1.29
Recurrent mutation, gene conversion, or recombination at the human phenylalanine hydroxylase locus: evidence in French-Canadians and a catalog of mutations. Am J Hum Genet (1990) 1.28
Application of the ovarian teratoma mapping method in the mouse. Genetics (1983) 1.28
Phenylketonuria and other phenylalanine hydroxylation mutants in man. Annu Rev Genet (1980) 1.27
X-autosome translocations in the mouse: total inactivation versus partial inactivation of the X chromosome. Adv Genet (1970) 1.27
Management of hereditary metabolic disease. The role of allied health personnel. N Engl J Med (1971) 1.26
A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci U S A (1999) 1.25
Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am J Hum Genet (1997) 1.25
Male and female mouse DNAs can be discriminated using retroviral probes. Nature (1982) 1.24
Mouse microcytic anaemia caused by a defect in the gene encoding the globin enhancer-binding protein NF-E2. Nature (1993) 1.23
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab (2010) 1.22
Outcome of early and long-term management of classical maple syrup urine disease. Pediatrics (1981) 1.22
Late replication in an X-autosome translocation in the mouse: correlation with genetic inactivation and evidence for selective effects during embryogenesis. Proc Natl Acad Sci U S A (1979) 1.21
PAH Mutation Analysis Consortium Database: a database for disease-producing and other allelic variation at the human PAH locus. Nucleic Acids Res (1996) 1.21
The characterization of hereditary abnormalities of keratin: Clouston's ectodermal dysplasia. Birth Defects Orig Artic Ser (1971) 1.20
Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc Natl Acad Sci U S A (1999) 1.20